RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development

被引:23
作者
Thaler, S. [1 ]
Schmidt, M. [2 ]
Schad, A. [3 ]
Sleeman, J. P. [4 ]
机构
[1] Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, D-68167 Mannheim, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Obstet & Gynecol, Mainz, Germany
[3] Johannes Gutenberg Univ Mainz, Dept Pathol, D-6500 Mainz, Germany
[4] Kernforschungszentrum Karlsruhe GmbH, Inst Genet & Toxikol, D-7500 Karlsruhe, Germany
关键词
RASSF1A; estrogen receptor alpha; senescence; breast cancer inhibition; ONCOGENE-INDUCED SENESCENCE; C-MYC; ACTIVATION; BCL-2; DNA; CELLS; MICE; TRANSFORMATION; PROLIFERATION; METHYLATION;
D O I
10.1038/onc.2011.658
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Ras association domain family 1 isoform A (RASSF1A) is a tumor suppressor whose inactivation is implicated in the development of many human cancers, including breast carcinomas. Little is known about the tumor-suppressive function of RASSF1A in breast tissue and whether its inactivation is mechanistically involved in the initiation and progression of breast tumors. Here, we show that RASSF1A inhibits breast cancer growth in vivo, and suppresses estrogen receptor (ER alpha) expression and function. Reconstitution of RASSF1A in MCF7 cells led to decreased ER alpha levels and reduced sensitivity to estrogen (E2). Concomitantly, we observed decreased expression of Id1 as well as the E2-responsive genes Bcl-2 and c-Myc that cooperatively contribute to the immortalization and transformation of breast epithelial cells. This downregulation was associated with induction of cell-cycle arrest and senescence that constitute early barriers to cancer initiation and progression. Knockdown of ER alpha showed that downregulation of ER alpha suffices to increase senescence and inhibit expression of Bcl-2, c-Myc and Id1. However, enforced expression of ER alpha only partially rescued RASSF1A-mediated growth inhibition and senescence, suggesting that suppression of ER alpha expression and activity is not the only mechanism by which RASSF1A inhibits growth and survival of breast cancer cells. Ectopic expression of Bcl-2, c-Myc and Id1 had little or no effect on RASSF1A-mediated growth arrest, indicating that RASSF1A acts dominantly over these oncogenes. Mechanistically, RASSF1A was found to suppress ER alpha expression through Akt1. It also transiently inhibited ER alpha-induced Ras-MAPK activity after exposure of cells to E2. Together, our data show that RASSF1A acts as a tumor suppressor in ER alpha+ mammary epithelial cells, in part through inhibiting ER alpha expression and activity. These findings suggest that RASSF1A has a key role in suppressing the transformation of human breast epithelial cells and ER alpha+ breast cancer initiation.
引用
收藏
页码:4912 / 4922
页数:11
相关论文
共 53 条
[1]   Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints [J].
Bartkova, Jirina ;
Rezaei, Nousin ;
Liontos, Michalis ;
Karakaidos, Panagiotis ;
Kletsas, Dimitris ;
Issaeva, Natalia ;
Vassiliou, Leandros-Vassilios F. ;
Kolettas, Evangelos ;
Niforou, Katerina ;
Zoumpourlis, Vassilis C. ;
Takaoka, Munenori ;
Nakagawa, Hiroshi ;
Tort, Frederic ;
Fugger, Kasper ;
Johansson, Fredrik ;
Sehested, Maxwell ;
Andersen, Claus L. ;
Dyrskjot, Lars ;
Orntoft, Torben ;
Lukas, Jiri ;
Kittas, Christos ;
Helleday, Thomas ;
Halazonetis, Thanos D. ;
Bartek, Jiri ;
Gorgoulis, Vassilis G. .
NATURE, 2006, 444 (7119) :633-637
[2]   Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer [J].
Blanco-Aparicio, Carmen ;
Perez-Gallego, Lucia ;
Pequeno, Belen ;
Leal, Juan F. M. ;
Renner, Oliver ;
Carnero, Amancio .
CARCINOGENESIS, 2007, 28 (03) :584-594
[3]   Integrative genomic approaches identify IKBKE as a breast cancer oncogene [J].
Boehm, Jesse S. ;
Zhao, Jean J. ;
Yao, Jun ;
Kim, So Young ;
Firestein, Ron ;
Dunn, Ian F. ;
Sjostrom, Sarah K. ;
Garraway, Levi A. ;
Weremowicz, Stanislawa ;
Richardson, Andrea L. ;
Greulich, Heidi ;
Stewart, Carly J. ;
Mulvey, Laura A. ;
Shen, Rhine R. ;
Ambrogio, Lauren ;
Hirozane-Kishikawa, Tomoko ;
Hill, David E. ;
Vidal, Marc ;
Meyerson, Matthew ;
Grenier, Jennifer K. ;
Hinkle, Greg ;
Root, David E. ;
Roberts, Thomas M. ;
Lander, Eric S. ;
Polyak, Kornelia ;
Hahn, William C. .
CELL, 2007, 129 (06) :1065-1079
[4]   Transformation of human and murine fibroblasts without viral oncoproteins [J].
Boehm, JS ;
Hession, MT ;
Bulmer, SE ;
Hahn, WC .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (15) :6464-6474
[5]   Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α -: A new model for anti-estrogen resistance [J].
Campbell, RA ;
Bhat-Nakshatri, P ;
Patel, NM ;
Constantinidou, D ;
Ali, S ;
Nakshatri, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) :9817-9824
[6]   PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells [J].
Castoria, G ;
Migliaccio, A ;
Bilancio, A ;
Di Domenico, M ;
de Falco, A ;
Lombardi, M ;
Fiorentino, R ;
Varricchio, L ;
Barone, MV ;
Auricchio, F .
EMBO JOURNAL, 2001, 20 (21) :6050-6059
[7]   Identification of a novel estrogen receptor β1 binding partner, inhibitor of differentiation-1, and role of ERβ1 in human breast cancer cells [J].
Chen, Li ;
Qiu, Juhui ;
Yang, Cheng ;
Yang, Xinghua ;
Chen, Xianchun ;
Jiang, Jun ;
Luo, Xiangdong .
CANCER LETTERS, 2009, 278 (02) :210-219
[8]   BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis [J].
Cheng, EHYA ;
Wei, MC ;
Weiler, S ;
Flavell, RA ;
Mak, TW ;
Lindsten, T ;
Korsmeyer, SJ .
MOLECULAR CELL, 2001, 8 (03) :705-711
[9]  
Clarke RB, 1997, CANCER RES, V57, P4987
[10]   International Union of Pharmacology.: LXIV.: Estrogen receptors [J].
Dahlman-Wright, Karin ;
Cavailles, Vincent ;
Fuqua, Suzanne A. ;
Jordan, V. Craig ;
Katzenellenbogen, John A. ;
Korach, Kenneth S. ;
Maggi, Adriana ;
Muramatsu, Masami ;
Parker, Malcolm G. ;
Gustafsson, Jan-Ake .
PHARMACOLOGICAL REVIEWS, 2006, 58 (04) :773-781